Molecularly targeted therapy for hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Science

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1349-7006.2008.01006.xPMID 19038007PMCID PMC11159429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy

  2008cited by this paper
• Death through a tragedy: mitotic catastrophe

  2008cited by this paper
• Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

  2008cited by this paper
• AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

  2007cited by this paper
• Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)

  2007cited by this paper
• Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy.

  2007cited by this paper
• Cell cycle kinases in cancer.

  2007cited by this paper
• Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Chromosomal passengers: conducting cell division

  2007cited by this paper
• Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007cited by this paper
• AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis

  2007cited by this paper
• Disrupting insulin-like growth factor signaling as a potential cancer therapy

  2007cited by this paper
• MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to Aneuploidy

  2007cited by this paper
• A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results

  2007cited by this paper
• Targeting the mTOR signaling network in cancer.

  2007cited by this paper
• Hepatocellular carcinoma pathogenesis: from genes to environment

  2006cited by this paper
• Epidermal growth factor receptor (EGFR) signaling in cancer.

  2006cited by this paper
• New feasibility study design with hepatocellular carcinoma: A phase I/II study of TSU-68, an oral angiogenesis inhibitor.

  2006cited by this paper
• Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

  2006cited by this paper
• Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.

  2006cited by this paper
• Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

  2006cited by this paper
• Validating Aurora B as an anti-cancer drug target

  2006cited by this paper
• Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.

  2006cited by this paper
• Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial.

  2006cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation.

  2006cited by this paper
• PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity

  2006cited by this paper
• Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.

  2006cited by this paper
• Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma

  2006cited by this paper
• Biology of vascular endothelial growth factors

  2006cited by this paper
• Impact of IGF‐1R/EGFR cross‐talks on hepatoma cell sensitivity to gefitinib

  2006cited by this paper
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

  2005cited by this paper
• IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

  2005cited by this paper
• Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts.

  2005cited by this paper
• AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

  2005cited by this paper
• The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

  2005cited by this paper
• Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

  2005cited by this paper
• The biology of vascular endothelial growth factors.

  2005cited by this paper
• A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Proteasome inhibition as a novel therapeutic target in human cancer.

  2005cited by this paper
• IGF-1: old growth factor shines as new drug target.

  2005cited by this paper
• IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC)

  2005cited by this paper
• IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy

  2005cited by this paper
• Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance.

  2004cited by this paper
• VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

  2004cited by this paper
• Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Aurora-kinase inhibitors as anticancer agents

  2004cited by this paper
• Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC).

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004cited by this paper
• Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• The Role of the IGF Axis in Hepatocarcinogenesis

  2003cited by this paper
• Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma

  2003cited by this paper
• Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

  2003cited by this paper
• The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint

  2003cited by this paper
• A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

  2003cited by this paper
• Smart Weapons Prove Tough to Design

  2002cited by this paper
• Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma

  2002cited by this paper
• Cancer drugs. Smart weapons prove tough to design.

  2002cited by this paper
• Oncogenic signal transduction and therapeutic strategy for hepatocellular carcinoma.

  2002cited by this paper
• Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.

  2001cited by this paper
• Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma

  2001cited by this paper
• Results of surgical and nonsurgical treatment for small‐sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan

  2000cited by this paper
• Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis.

  2000cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000cited by this paper
• SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

  2000cited by this paper
• Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

  1999cited by this paper
• The increasing incidence of hepatocellular carcinoma.

  1999cited by this paper
• Regulation of angiogenesis in human hepatomas: possible involvement of p53-inducible inhibitor of vascular endothelial cell proliferation.

  1999cited by this paper
• The proteasome inhibitor PS-341 in cancer therapy.

  1999cited by this paper
• Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.

  1999cited by this paper
• Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver

  1998cited by this paper
• Expression of vascular endothelial growth factor in human hepatocellular carcinoma

  1998cited by this paper
• Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma.

  1998cited by this paper
• Biological effects of human insulin receptor substrate‐1 overexpression in hepatocytes

  1997cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Neoplastic Transformation Induced by Insulin Receptor Substrate-1 Overexpression Requires an Interaction with Both Grb2 and Syp Signaling Molecules*

  1996cited by this paper
• Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis.

  1996cited by this paper
• Insulin Receptor Substrate 1 Overexpression in Human Hepatocellular Carcinoma Cells Prevents Transforming Growth Factor β1-induced Apoptosis

  1996cited by this paper
• Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor

  1996cited by this paper
• IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance

  1996cited by this paper
• A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype.

  1996cited by this paper
• The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma.

  1996cited by this paper

• Targeting TCF21-TCF3 heterodimer in tumor-associated pericytes attenuates hematogenous metastasis by restoring pericyte gatekeeper function

  2026cites this paper
• Targeted therapy for liver cancer: Current status and future directions.

  2025cites this paper
• Hyaluronic-Acid-Coated Sterosome for Dasatinib Delivery in Hepatocellular Carcinoma: Preparation, Physicochemical Characterization, and In Vitro Evaluation

  2025cites this paper
• Injectable nanocomposite hydrogels for targeted intervention in cancer, wound healing, and bone and myocardial tissue engineering

  2025cites this paper
• Ferroptosis-Related Long Non-coding RNA Predicts Prognosis Model of Hepatocellular Carcinoma

  2022cites this paper
• NSUN2-mediated mRNA m5C Modification Regulates the Progression of Hepatocellular Carcinoma

  2022cites this paper
• Anticancer activity of L- Glutaminase obtained from Bacillus subtilis

  2021cites this paper
• STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway

  2021cites this paper
• The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma

  2021cites this paper
• Circular RNA circRHOBTB3 is downregulated in hepatocellular carcinoma and suppresses cell proliferation by inhibiting miR-18a maturation

  2021cites this paper
• STK 39 is a novel kinase contributing to the progression of hepatocellular 1 carcinoma by the PLK 1 / ERK signaling pathway 2

  2020cites this paper
• Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin

  2020cites this paper
• Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma.

  2019cites this paper
• Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma

  2019cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• Precision medicine based on surgical oncology in the era of genome‐scale analysis and genome editing technology

  2018cites this paper
• STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration.

  2018cites this paper
• Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients

  2017cites this paper
• Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies

  2017cites this paper
• Chapter 13 Insulin-Like Growth Factor-II : Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2017cites this paper
• Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives

  2017cites this paper
• Mexican consensus on the diagnosis and management of hepatocellular carcinoma

  2017cites this paper
• Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data

  2017cites this paper
• CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis

  2017cites this paper
• Phytochemicals and PI3K Inhibitors in Cancer—An Insight

  2017cites this paper
• Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma.

  2017cites this paper
• Hydration-Mediated Effects of Saccharide Stereochemistry on Protein Heat Stability

  2017cites this paper
• Validierung relevanter Prognosefaktoren des Leberzellkarzinoms in Bezug auf Therapiestrategie und Outcome

  2017cites this paper
• A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells

  2016cites this paper
• In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer

  2016cites this paper
• Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells

  2016cites this paper
• Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

  2016cites this paper
• Effect of rapamycin on endometriosis in mice

  2016cites this paper
• A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

  2016cites this paper
• Influence of bioactive sulfated polysaccharide-protein complexes on hepatocarcinogenesis, angiogenesis and immunomodulatory activities.

  2016cites this paper
• Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC

  2015cites this paper
• Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma

  2015cites this paper
• Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer

  2015cites this paper
• Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.

  2015cites this paper
• Anti-angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab.

  2015cites this paper
• Current and future treatments for hepatocellular carcinoma.

  2015cites this paper
• Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.

  2015cites this paper
• USP 39 promotes the growth of human hepatocellular carcinoma in vitro and in vivo

  2015cites this paper
• Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.

  2015cites this paper
• Phytochemical Analysis and Anti-cancer Investigation of Boswellia serrata Bioactive Constituents In Vitro.

  2015influential citation
• Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.

  2015cites this paper
• MicroRNAs in Nonalcoholic Fatty Liver Disease: Novel Biomarkers and Prognostic Tools during the Transition from Steatosis to Hepatocarcinoma

  2014cites this paper
• Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

  2014cites this paper
• Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis

  2014cites this paper
• Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular

  2014cites this paper
• Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells

  2014cites this paper
• Brain metastasis from gastrointestinal cancers: a systematic review

  2014cites this paper
• Multiplex in vitro and in vivo RNAi screening to identify treatment response modifiers of targeted therapies in HCC

  2014influential citation
• Small Molecule Therapeutics Combinatorial Therapy Using Dovitinib and ICI 182 . 780 ( Fulvestrant ) Blocks Tumoral Activity of Endometrial Cancer Cells

  2014cites this paper
• Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy

  2014cites this paper
• A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma

  2014cites this paper
• Upregulation of heat shock factor 1 transcription activity is associated with hepatocellular carcinoma progression

  2014cites this paper
• Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo

  2014cites this paper
• AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma

  2014cites this paper
• Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

  2014cites this paper
• The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma

  2014influential citation
• Insulin-Like Growth Factor-II: Molecular-Targeted Therapy for Hepatocellular Carcinoma

  2013cites this paper
• In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma

  2013cites this paper
• Fluoro‐Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery

  2013cites this paper
• Deficiency of G‐protein‐coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis

  2013cites this paper
• Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature

  2013cites this paper
• The role of CDK1 in apoptin-induced apoptosis in hepatocellular carcinoma cells.

  2013cites this paper
• The role of Neuropilin 2 in hepatocellular carcinoma: from meta-analysis to target characterization

  2013influential citation
• All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.

  2013cites this paper
• Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

  2013cites this paper
• RETRACTED ARTICLE: Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cγ1-, Ca2+-, and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells

  2013cites this paper
• Actionable Gene Expression-Based Patient Stratification for Molecular Targeted Therapy in Hepatocellular Carcinoma

  2013cites this paper
• Understanding the biological context of NS5A-host interactions in HCV infection: a network-based approach.

  2013cites this paper
• Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

  2013cites this paper
• The role of CDK 1 in apoptin-induced apoptosis in hepatocellular carcinoma cells

  2013cites this paper
• Promoting Antitumor Activities of Hydroxycamptothecin by Encapsulation into Acid-Labile Nanoparticles Using Electrospraying

  2013cites this paper
• Efecto de la melatonina sobre la proliferación, apoptosis y angiogénesis en un modelo in vitro de hepatocarcinoma

  2013influential citation
• Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells.

  2013cites this paper
• HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

  2013cites this paper
• Sorafenib and its derivative SC‐49 sensitize hepatocellular carcinoma cells to CS‐1008, a humanized anti‐TNFRSF10B (DR5) antibody

  2013cites this paper
• YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models

  2013cites this paper
• Curcumin-Induced Apoptosis in Human Hepatocellular Carcinoma J5 Cells: Critical Role of Ca+2-Dependent Pathway

  2012cites this paper
• The role of N-acetylglucosaminyltransferases V in the malignancy of human hepatocellular carcinoma.

  2012cites this paper
• Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy

  2012cites this paper
• Angiotensin II Induces Angiogenic Factors Production Partly Via AT1/JAK2/STAT3/SOCS3 Signaling Pathway in MHCC97H Cells

  2012cites this paper
• Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.

  2012cites this paper
• Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma

  2012cites this paper
• Identification of new candidate therapeutic target genes in triple-negative breast cancer.

  2012cites this paper
• A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts

  2012influential citation
• Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation

  2012cites this paper
• Hepatocellular carcinoma: natural history, current management, and emerging tools

  2012cites this paper
• Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma

  2012cites this paper
• Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA

  2012cites this paper
• TNF-Dependent Signaling Pathways in Liver Cancer: Promising Targets for Therapeutic Strategies?

  2012cites this paper
• Solitary liver lesions of indeterminate malignancy--outcome following surgical resection.

  2012cites this paper
• Celastrol Suppresses Growth and Induces Apoptosis of Human Hepatocellular Carcinoma through the Modulation of STAT3/JAK2 Signaling Cascade In Vitro and In Vivo

  2012cites this paper
• A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.

  2012cites this paper
• Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects.

  2012cites this paper
• Involvement of phosphatidylinositol 3-kinase/Akt pathway in gemcitabine-induced apoptosis-like cell death in insulinoma cell line INS-1.

  2012cites this paper
• Molecular targeted therapies in hepatocellular carcinoma.

  2012cites this paper